CA2816999A1 - Compositions and methods for nanopolymer-based nucleic acid delivery - Google Patents

Compositions and methods for nanopolymer-based nucleic acid delivery Download PDF

Info

Publication number
CA2816999A1
CA2816999A1 CA2816999A CA2816999A CA2816999A1 CA 2816999 A1 CA2816999 A1 CA 2816999A1 CA 2816999 A CA2816999 A CA 2816999A CA 2816999 A CA2816999 A CA 2816999A CA 2816999 A1 CA2816999 A1 CA 2816999A1
Authority
CA
Canada
Prior art keywords
nucleic acid
methods
compositions
nanopolymer
acid delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2816999A
Other languages
English (en)
French (fr)
Inventor
John N. Vournakis
Marina V. Demcheva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Publication of CA2816999A1 publication Critical patent/CA2816999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA2816999A 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery Abandoned CA2816999A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US61/410,863 2010-11-06
US41135810P 2010-11-08 2010-11-08
US61/411,358 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Publications (1)

Publication Number Publication Date
CA2816999A1 true CA2816999A1 (en) 2012-05-10

Family

ID=46025153

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816999A Abandoned CA2816999A1 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Country Status (10)

Country Link
US (3) US20130287853A1 (https=)
EP (1) EP2635261B1 (https=)
JP (2) JP6029591B2 (https=)
CN (2) CN108743562A (https=)
AU (3) AU2011323078B2 (https=)
CA (1) CA2816999A1 (https=)
ES (1) ES2763432T3 (https=)
IL (1) IL226170B (https=)
MX (1) MX358050B (https=)
WO (1) WO2012061803A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008219065B2 (en) 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
BR112012025844A2 (pt) 2010-04-15 2017-07-18 Marine Polymer Tech Inc uso de nanofibras snag
WO2012061803A2 (en) * 2010-11-06 2012-05-10 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
CA2487564A1 (en) * 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
US20100150960A1 (en) * 2006-09-22 2010-06-17 The United States Of America, As Represented By The Secretary,Department Of Health And Human Servi Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
BRPI0807065A2 (pt) * 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
WO2012061803A2 (en) * 2010-11-06 2012-05-10 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery

Also Published As

Publication number Publication date
AU2011323078A1 (en) 2013-05-02
MX358050B (es) 2018-08-03
JP6029591B2 (ja) 2016-11-24
CN103282024A (zh) 2013-09-04
US20230157971A1 (en) 2023-05-25
WO2012061803A3 (en) 2012-08-16
MX2013005016A (es) 2014-03-12
JP2016164181A (ja) 2016-09-08
IL226170A0 (en) 2013-07-31
AU2016201640A1 (en) 2016-04-07
JP2014500250A (ja) 2014-01-09
AU2011323078B2 (en) 2016-04-14
IL226170B (en) 2018-11-29
EP2635261B1 (en) 2019-10-23
US20130287853A1 (en) 2013-10-31
AU2013203247A1 (en) 2013-05-09
CN108743562A (zh) 2018-11-06
WO2012061803A2 (en) 2012-05-10
ES2763432T3 (es) 2020-05-28
EP2635261A4 (en) 2014-09-17
US20170128382A1 (en) 2017-05-11
EP2635261A2 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
CA2816999A1 (en) Compositions and methods for nanopolymer-based nucleic acid delivery
MX342439B (es) Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos.
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
WO2014004993A3 (en) Methods of reducing ldl-p
NZ603411A (en) Pazopanib compositions and their use in treating ocular diseases
WO2013006729A3 (en) Cannabinoid receptor binding agents, compositions and methods
WO2010075072A3 (en) Long circulating nanoparticles for sustained release of therapeutic agents
WO2012000103A8 (en) Methods of targeting pten mutant diseases and compositions therefor
WO2013041975A3 (en) Pyrethroid formulations
WO2009089365A3 (en) Therapeutic formulations based on asiatic acid and selected salts thereof
WO2012001074A3 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
WO2013087734A3 (en) Functionalised silicon nanoparticles
WO2011069010A3 (en) Amantadine compositions and methods of use
WO2011129588A3 (ko) 경피흡수용 고분자-리포좀 나노복합체 조성물 및 그 제조방법
PH12013500923A1 (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
NZ595904A (en) A novel formulation of meloxicam
HK1200695A1 (en) Optimised subcutaneous therapeutic agents
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
WO2009050696A3 (en) Composition and method for cell activation and tissue repair using nanoparticles and light
JP2014500250A5 (https=)
WO2010109176A3 (en) Parenteral pharmaceutical composition for use in gene therapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20171107